What It Is
Modius Spero is a prescription-only, non-invasive neuromodulation headset developed by Neurovalens. It received FDA De Novo authorization on May 26, 2026 — the first device in a newly created regulatory classification for non-invasive neurostimulation treatment of PTSD. The device delivers low-level electrical stimulation to the vestibular nerve via electrode pads placed behind the ears, targeting deep brain structures associated with the stress response.
How It Works
The vestibular system — the inner ear's balance and spatial orientation network — has direct neural connections to the brainstem, amygdala, and hypothalamus. Modius Spero exploits these pathways to modulate stress-response circuitry without requiring cranial penetration or implantation.
Treatment consists of 30-minute daily sessions, self-administered at home under clinical supervision. The device connects to a companion app that guides electrode placement, controls stimulation parameters, and tracks symptom progression over time.
The mechanism is distinct from other consumer neuromodulation approaches:
- Vagus nerve stimulators (Pulsetto, Nurosym) target the auricular branch of CN X
- tDCS devices (Flow FL-100) deliver current to cortical regions
- Modius Spero targets the vestibular nerve (CN VIII), accessing subcortical stress circuits through a different anatomical pathway
The Clinical Evidence
The FDA authorization was supported by a pivotal 12-week randomized, sham-controlled trial involving 383 adult participants with clinical PTSD diagnoses — a substantially larger trial than most consumer neuromodulation devices have produced.
Key results:
- ~66% of active-device participants reported clinically meaningful improvement in PTSD symptoms
- Statistically significant improvements in insomnia severity were also documented
- Safety profile was favorable, with no serious adverse events reported
- The sham-controlled design (participants wore identical devices with inactive stimulation) provides stronger evidence than open-label studies
What we don't know: The specific PTSD Checklist (PCL-5) score reductions, long-term durability beyond 12 weeks, and whether effects persist after treatment discontinuation have not been fully published as of this review.
Who It's For
Modius Spero is indicated for adults aged 22 and older with a clinical PTSD diagnosis. It is prescription-only — you cannot purchase it over the counter. The device is being rolled out initially through the U.S. Department of Veterans Affairs, with broader clinical availability expected in late 2026.
This is not a wellness device. It is positioned as a clinical tool, prescribed and monitored by healthcare professionals as part of a comprehensive PTSD care plan.
What It Costs
Pricing has not been publicly disclosed as of August 2026. Given its prescription-only, FDA-authorized status, the device may qualify for insurance reimbursement or VA coverage. Previous Modius products (Modius Sleep) were priced around $400-500.
The Body-Mind Perspective
Modius Spero represents a significant development for the nervous system regulation space. The vestibular pathway it targets — connecting the inner ear to the brainstem and limbic system — is the same system engaged by balance training, proprioceptive exercises, and certain somatic therapy approaches. The fact that electrical stimulation of this pathway produces measurable PTSD symptom reduction validates what body-oriented trauma therapists have long observed: that vestibular and proprioceptive input can modulate the stress response.
For practitioners, Modius Spero creates a legitimate clinical reference point for discussing vestibular-stress connections with clients. However, the device itself is not available outside clinical supervision.
Bottom Line
Evidence strength: Strong. A 383-person sham-controlled trial with FDA De Novo authorization is a substantially higher evidence bar than most products in this category. The vestibular nerve pathway is well-characterized in neuroscience literature, and the clinical data support the mechanism. The main limitation is that long-term outcome data and full publication of trial results are still pending.
Source
- FDA De Novo Authorization — Modius Spero. — U.S. Food and Drug Administration
- Modius Spero clinical trial results. — Psychiatric Times
